Nyrop M, Zweifler A J
University of Michigan, Department of Internal Medicine, Ann Arbor 48109-0356.
J Hypertens. 1988 Apr;6(4):263-9.
The major findings of a review of the literature on platelet aggregation in hypertensive human subjects and the effects of antihypertensive agents were as follows: (1) There is an increased platelet aggregatory response to epinephrine and ADP in hypertensives with MAP greater than 120 mmHg. (2) Treatment with propranolol decreases the aggregatory response to ADP, but it may enhance the response to epinephrine. (3) Treatment with calcium blockers in normotensives decreases the aggregatory response to epinephrine. Further work needs to be done to answer the questions raised by this review. Since the major goal, yet unachieved, of antihypertensive therapy is reduction of the incidence of CHD, the anti-thrombotic or thrombotic potential of antihypertensive agents must be known. Future clinical trials of drug therapy for hypertension should be designed to include at least a determination of platelet aggregation in response to both ADP and epinephrine.
(1) 平均动脉压大于120 mmHg的高血压患者对肾上腺素和二磷酸腺苷（ADP）的血小板聚集反应增强。(2) 用普萘洛尔治疗可降低对ADP的聚集反应，但可能增强对肾上腺素的反应。(3) 血压正常者用钙通道阻滞剂治疗可降低对肾上腺素的聚集反应。需要进一步开展工作以回答本综述提出的问题。由于抗高血压治疗尚未实现的主要目标是降低冠心病的发病率，因此必须了解抗高血压药物的抗血栓形成或促血栓形成潜力。未来的高血压药物治疗临床试验应设计为至少包括测定对ADP和肾上腺素的血小板聚集情况。
